Remove 2021 Remove Pharmacokinetics Remove Trials
article thumbnail

Time for change: non-human primates in drug research

Drug Target Review

Their unique suitability has made them valuable for evaluating pharmacokinetics, toxicology and safety in drug candidates before human clinical trials. Since 2021, institutions like the National Primate Research Centers (NPRCs) have reported their inability to meet up to two-thirds of requests for research monkeys.

article thumbnail

Crinecerfont

New Drug Approvals

2] History Crinecerfont’s approval is based on two randomized, double-blind, placebo-controlled trials in 182 adults and 103 children with classic congenital adrenal hyperplasia. [2] 2] In the first trial, 122 adults received crinecerfont twice daily and 60 received placebo twice daily for 24 weeks. [2] 2021 Nov 30;186(1):R1-R14.

FDA 62
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Landiolol

New Drug Approvals

elimination half-life (min) cardio-selectivity (1/2) metabilization Landiolol 4 250 pseudocholinesterases Esmolol 9 30 ery-esterases Metoprolol 420 3 cytochrom P2D6 (Leber) History The beneficial effects of landiolol have been demonstrated in over sixty clinical trials (pubmed search -August 2018). 28 October 2021. February 2021).

FDA 62
article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. The SELECT trial set out to understand whether the drug has similar effect on patients without diabetes. As of mid-2024, this includes at least 650 Phase I-IV trials, with about 430 of those already ongoing.

article thumbnail

Limited Evidence for Nalfmefene

Common Sense for Drug Policy Blog

Limited Evidence for Nalfmefene "In 2021, due to the widespread availability of high-potency synthetic opioids like fentanyl, the US FDA approved two high-dose naloxone products, an 8 mg IN spray (Kloxxado) and a 5 mg IM injectable (Zimhi). mg IM vs. 8 mg IN and 2 mg IM vs. 5 mg IM, respectively). In 2023, the FDA approved a 2.7

article thumbnail

AZVUDINE

New Drug Approvals

9] Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)). It was approved in China in 2021 as a first-in-class treatment for human immunodeficiency virus (HIV). 2021, 6, 414. (9) 6] [7] Azvudine was first discovered in 2007. [8]

RNA 62
article thumbnail

Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021

The Pharma Data

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine.